Walleye Capital LLC Buys Shares of 491,466 Rezolute, Inc. (NASDAQ:RZLT)

Walleye Capital LLC purchased a new stake in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 491,466 shares of the company's stock, valued at approximately $2,408,000. Walleye Capital LLC owned about 0.85% of Rezolute at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. purchased a new position in shares of Rezolute during the third quarter valued at about $42,000. MML Investors Services LLC purchased a new position in shares of Rezolute during the 3rd quarter worth approximately $57,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after acquiring an additional 9,000 shares during the period. Virtu Financial LLC raised its position in shares of Rezolute by 58.0% in the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock worth $126,000 after acquiring an additional 9,551 shares in the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Rezolute in the 4th quarter valued at approximately $277,000. Hedge funds and other institutional investors own 82.97% of the company's stock.

Rezolute Price Performance

Rezolute stock traded up $0.39 during mid-day trading on Monday, reaching $3.14. The stock had a trading volume of 2,273,991 shares, compared to its average volume of 514,224. Rezolute, Inc. has a one year low of $2.22 and a one year high of $6.19. The company has a 50-day moving average price of $3.44 and a two-hundred day moving average price of $4.47. The company has a market capitalization of $190.08 million, a price-to-earnings ratio of -2.57 and a beta of 0.97.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11. On average, equities research analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Insider Buying and Selling at Rezolute

In other Rezolute news, CEO Nevan C. Elam bought 12,302 shares of the firm's stock in a transaction on Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, with a total value of $35,060.70. Following the transaction, the chief executive officer now owns 224,119 shares in the company, valued at $638,739.15. This represents a 5.81 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Wladimir Hogenhuis bought 10,000 shares of the stock in a transaction on Tuesday, February 18th. The shares were bought at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the purchase, the director now directly owns 77,267 shares in the company, valued at approximately $363,154.90. This trade represents a 14.87 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 39,060 shares of company stock worth $130,694. Insiders own 18.39% of the company's stock.

Analyst Upgrades and Downgrades

RZLT has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price target on shares of Rezolute in a research note on Thursday, February 13th. JMP Securities upped their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Guggenheim reissued a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Finally, Craig Hallum upgraded shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $26.43.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.